AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $58.64
  • 50 Day Moving Average: $4989.09
  • 200 Day Moving Average: $4528.23
  • 52-Week Range: £12,650,000 - GBX 3,680
  • Trailing P/E Ratio: 27.30
  • P/E Growth: 2.38
  • Market Cap: $60.43B
  • Outstanding Shares: 1,265,000,000
Additional Links:

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Ratings, 14 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.23)
Consensus Price Target: GBX 4,966.24

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
DateFirmActionRatingPrice TargetDetails
10/26/2016Bryan, Garnier & CoReiterated RatingBuyGBX 5,220View Rating Details
10/26/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 4,900View Rating Details
10/26/2016Liberum CapitalReiterated RatingHoldGBX 5,200View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 5,333View Rating Details
10/19/2016Goldman Sachs Group Inc.Set Price TargetSellGBX 4,000View Rating Details
10/13/2016Jefferies GroupBoost Price TargetBuyGBX 5,800 -> GBX 6,000View Rating Details
10/11/2016Deutsche Bank AGReiterated RatingBuyGBX 6,200View Rating Details
10/7/2016Shore CapitalReiterated RatingHoldView Rating Details
10/7/2016Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details
10/5/2016Citigroup Inc.Reiterated RatingBuyGBX 6,000View Rating Details
9/30/2016BNP ParibasReiterated RatingNeutralGBX 5,200View Rating Details
9/14/2016Societe GeneraleReiterated RatingBuyGBX 7,000View Rating Details
9/8/2016Berenberg BankReiterated RatingBuyGBX 5,550View Rating Details
8/25/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
8/19/2016Morgan StanleyBoost Price TargetOverweightGBX 5,000 -> GBX 5,800View Rating Details
8/11/2016HSBCReiterated RatingHoldGBX 4,700View Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
4/25/2016Barclays PLCReiterated RatingEqual WeightGBX 5,000View Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
11/16/2015Kepler Capital MarketsReiterated RatingReduceGBX 3,700View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
4/9/2015Redburn PartnersUpgradeBuyView Rating Details
11/7/2014Cenkos Securities LtdReiterated RatingHoldView Rating Details
(Data available from 10/26/2014 forward)


Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by


Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $4.09 EPS


Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)


Latest Headlines for AstraZeneca plc (LON:AZN)
News IconHaitong Securities Gives Burberry Group PLC Price Target With Potential -3.28% Downside (LON:AZN) - October 26 at 12:41 PM
News IconStocks under Profitability Radar: AstraZeneca PLC (NYSE:AZN ... - Street Wise Report (press release) (blog) (LON:AZN) - October 25 at 3:44 PM
News IconTraders Recap - AstraZeneca PLC's (AZN) - Hot Stocks Point (LON:AZN) - October 25 at 8:33 AM logoMerck wins early U.S. approval for Keytruda in untreated lung cancer (LON:AZN) - October 25 at 8:33 AM
News IconIs AstraZeneca PLC(NYSE: AZN), a large market cap stock a smart ... - The Daily Leicester (LON:AZN) - October 24 at 8:35 AM
News IconAstraZeneca PLC's (AZN): Monitor the Current Moves | Hot Stocks ... - Hot Stocks Point (LON:AZN) - October 21 at 8:42 PM logo18 October 2016 FDA accepts for review New Drug Application for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia Corporate Press Release (LON:AZN) - October 18 at 8:32 AM logoAstraZeneca Plc (NYSE:AZN) Sends Synairgen Plummeting On Ditching Asthma Drug Trial (LON:AZN) - October 17 at 8:34 AM
News IconAnalysts At Jefferies Reiterated Astrazeneca (LON:AZN) As Buy (LON:AZN) - October 15 at 8:34 AM
News IconAstraZeneca plc 21.2% Potential Upside Indicated by Jefferies International (LON:AZN) - October 15 at 8:34 AM
News IconStock Momentum Curbed Pre-Bell, Gapping Down: AstraZeneca PLC (NYSE:AZN) - CSZ News (LON:AZN) - October 13 at 12:15 PM logoAstraZeneca Plc breached its 50 day moving average in a Bearish Manner : AZN-GB : October 13, 2016 (LON:AZN) - October 13 at 12:15 PM logoTop 5 Jefferies Big Pharma Stock Picks for Q4 (LON:AZN) - October 13 at 12:15 PM logoIt's lonely at the top for Britain's FTSE 100 index (LON:AZN) - October 13 at 12:15 PM logoIt's lonely at the top for FTSE 100 index (LON:AZN) - October 13 at 12:15 PM
News IconAstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital (LON:AZN) - October 12 at 3:57 PM logoSynairgen: AstraZeneca stopped asthma drug trial (LON:AZN) - October 12 at 3:57 PM
News IconLarge Cap Drug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) (LON:AZN) - October 12 at 3:57 PM
News IconDrug Manufacturers - Major: AstraZeneca PLC (NYSE:AZN) Position of the day (LON:AZN) - October 12 at 3:57 PM logoBUZZ-AstraZeneca: investor survey sees 50:50 chance for cancer combo (LON:AZN) - October 12 at 8:06 AM logo[$$] Computer revolution? Good investments still need the human touch (LON:AZN) - October 10 at 8:29 AM logoAstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies (LON:AZN) - October 9 at 3:37 PM logo'New day' in lung cancer as Merck drug shines, works with chemo (LON:AZN) - October 9 at 8:28 AM logoAstraZeneca signs $330 mln deal with J&J affiliate (LON:AZN) - October 7 at 3:43 PM
News IconAstraZeneca PLC's (AZN): Remarkable Runner - Hot Stocks Point (LON:AZN) - October 7 at 8:32 AM logoAstraZeneca signs $330 mln deal with J&J affiliate - MarketWatch (LON:AZN) - October 7 at 8:32 AM logo7 October 2016 AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US Corporate Press Release (LON:AZN) - October 7 at 8:32 AM logoBrigham and Women’s doctor wins $75M award for cardiovascular work (LON:AZN) - October 5 at 3:26 PM
News IconVolatile Mix Cap Mover- AstraZeneca PLC (NYSE:AZN), New Gold, Inc. (NYSE:NGD), Marriott International, Inc ... - Seneca Globe (LON:AZN) - October 5 at 8:35 AM logoAstraZeneca plc (ADR) (NYSE:AZN) Gets UK Approval For Tagrisso - Market Exclusive (LON:AZN) - October 5 at 8:35 AM logoAstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline (LON:AZN) - October 4 at 3:43 PM
News IconIs AstraZeneca PLC (NYSE:AZN), a large market cap stock a smart buy? (LON:AZN) - October 4 at 3:43 PM
News IconAllergan (AGN) Snaps Up Global Rights to AstraZeneca's (AZN) Crohn's Drug - Economic Calendar (LON:AZN) - October 3 at 3:40 PM
News IconLeading Stock of Friday- Astrazeneca PLC (NYSE:AZN) - Hot Stocks Point (LON:AZN) - October 3 at 8:30 AM
News IconAstraZeneca PLC Consolidating 350 California Jobs to the Bay Area (LON:AZN) - September 28 at 3:47 PM logoFacebook Founder’s Science Group Hires AstraZeneca Board Member (LON:AZN) - September 28 at 8:33 AM
News IconDrug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) Position of the day (LON:AZN) - September 24 at 9:01 AM
News IconWatch List - AstraZeneca PLC's (AZN) - Hot Stocks Point (LON:AZN) - September 23 at 8:45 AM logoIs this a better healthcare buy than AstraZeneca plc after today’s update? (LON:AZN) - September 23 at 8:45 AM logoPharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO (LON:AZN) - September 23 at 8:45 AM logoAstraZeneca Selects LLamasoft as Supply Chain Design Partner of Choice (LON:AZN) - September 21 at 4:38 PM logoAstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy (LON:AZN) - September 21 at 7:38 AM logo[$$] Opinions split on Witty regime at GSK (LON:AZN) - September 20 at 3:41 PM
News IconHC Stocks Review! Mylan NV (MYL), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release) (LON:AZN) - September 20 at 9:38 AM logoCiti Research Reevaluates Bristol-Myers, Lowers Price Target - Benzinga (LON:AZN) - September 20 at 9:38 AM logoAstraZeneca : *UBS RAISES ASTRAZENECA PRICE TARGET TO 5480 PENCE - 'BUY' (LON:AZN) - September 19 at 4:37 PM
News IconHigh Market Cap Stock of the Day – AstraZeneca PLC (NYSE:AZN) (LON:AZN) - September 19 at 4:37 PM logoTOP NEWS: AstraZeneca Sees Positive Results In Type-2 Diabetes Trial (LON:AZN) - September 16 at 8:59 AM logoAstraZeneca Diabetes Drug Combination Shows Promise in Study (LON:AZN) - September 16 at 8:59 AM logoAstrazeneca says Forxiga combination beats use of drug alone (LON:AZN) - September 16 at 8:59 AM


Last Updated on 10/26/2016 by Staff